RE: RNS - Tim McCarthy, CEO and Chairman, said: "ImmuPharma is entering a pivotal phase, focused on securing a commercial partnership for P14027 May 2026 10:20
"We have made meaningful progress in advancing P140 towards late-stage clinical development readiness.
Ok, that's great but without the funds to do the clinical trials, the readiness won't be worth much , imo
As stated before, Until IMM sign a deal with a company willing to spend the Major money necessary to do the clinical trials, it's a chip and a chair investment, imo